search
Back to results

Drug-Eluting Balloons vs Mimetic Stents for Popliteal Artery Disease

Primary Purpose

Popliteal Arterial Stenosis

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Pharmacoactive balloon angioplasty. Lutonix®
Mimetic stent.Supera®
Sponsored by
Hospital Universitari de Bellvitge
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Popliteal Arterial Stenosis focused on measuring Popliteal artery stenosis, Mimetic stent, Pharmacoactive balloon angioplasty, Chronic lower limb ischemia

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients diagnosed of critical lower limb ischemia according to the TASC (TransAtlantic Inter-Society Consensus) working group. Patients admitted to the Vascular Surgery Department of the Bellvitge Hospital University to treat critical lower limb ischemia for endovascular treatment. With involvement of the Popliteal artery in-between the Hunter's canal and the start of the tibial artery branch. WOCBP must use highly effective methods of contraception. Patients who sign the written informed consent. Exclusion Criteria: Patients diagnosed of critical lower limb ischemia according to the TASC working group undergoing medical treatment or open surgery. Patients requiring amputation. Patients who underwent previous revascularization of the same limb (same artery). The main involvement is from an arterial territory other than the popliteal artery. Pregnant women. Inability of overcoming the arterial lesion during the endovascular procedure. Affected artery's diameter <4 mm.

Sites / Locations

  • Hospital Universitari de BellvitgeRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Group A

Group B

Arm Description

Patients receiving pharmacoactive balloon angioplasty. Lutonix®

Patients receiving mimetic stent. Supera®

Outcomes

Primary Outcome Measures

Permeability
Degree of arterial permeability after intervention measured by arterial cartography with ultrasound at 3, 6 and 12 months.

Secondary Outcome Measures

Limb salvage rate
Number (percentage) of limbs that did not undergo further amputation.
Limb reintervention rate
Number (percentage) of limbs that required reintervention.
Deaths
Number (percentage) of deaths by any cause.

Full Information

First Posted
November 23, 2022
Last Updated
December 13, 2022
Sponsor
Hospital Universitari de Bellvitge
search

1. Study Identification

Unique Protocol Identification Number
NCT05651165
Brief Title
Drug-Eluting Balloons vs Mimetic Stents for Popliteal Artery Disease
Official Title
Comparative Study Between Drug-Eluting Balloons and Mimetic Stents for Popliteal Artery Disease Treatment in Patients With Chronic Lower Limb Ischemia
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2021 (Actual)
Primary Completion Date
January 2024 (Anticipated)
Study Completion Date
January 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hospital Universitari de Bellvitge

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
More advanced and severe cases of chronic lower limb ischemia (the so-called critical lower limb ischemia) are painful and limiting conditions that impact on patients' quality of life. Until now, the available evidence for the femoropopliteal area only defines open surgery or endovascular treatment indications. However, the best strategy for endovascular procedures is still unclear. The popliteal artery is a challenging anatomical site for balloon angioplasty alone and standard nitinol stenting angioplasty. This randomized clinical trial aims to assess the superiority of nitinol stent angioplasty compared to pharmacoactive balloon angioplasty to treat critical lower limb ischemia due to popliteal artery arteriosclerosis.
Detailed Description
Arteriosclerosis is a systemic and multi-etiological disease that causes arterial degeneration, narrowing their lumens and reducing perfusion in their respective territories. Chronic lower limb ischemia is one manifestation of arteriosclerosis. It may be initially asymptomatic, but patients usually present with pulselessness and intermittent lower limb claudication. More advanced and severe cases present with rest pain, the so-called critical lower limb ischemia. Critical lower limb ischemia usually benefits from revascularization and requires cautious surgical planning with complementary imaging tests able to locate the lesion site precisely. In our setting, the most used test is arterial cartography with doppler ultrasound. Afterward, surgeons should decide whether to perform open surgery or endovascular treatment. Until now, the available evidence for the femoropopliteal area only defines open surgery or endovascular treatment indications. However, the best strategy for endovascular procedures is still unclear. Given its anatomy, the popliteal artery undergoes many flexion-extension and rotational movements, making it a challenging site for balloon angioplasty alone (high incidence of restenosis) and standard nitinol stenting angioplasty (risk of stent fractures). Mimetic stents have been developed to overcome the risk of stent fractures. They consist of multiple intertwined nitinol wires that provide greater radial resistance and allow for even stress distribution. This randomized clinical trial aims to assess the superiority of nitinol stent angioplasty compared to pharmacoactive balloon angioplasty to treat critical lower limb ischemia due to popliteal artery arteriosclerosis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Popliteal Arterial Stenosis
Keywords
Popliteal artery stenosis, Mimetic stent, Pharmacoactive balloon angioplasty, Chronic lower limb ischemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Open label, parallel-group, randomized (1:1) clinical trial.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
110 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group A
Arm Type
Active Comparator
Arm Description
Patients receiving pharmacoactive balloon angioplasty. Lutonix®
Arm Title
Group B
Arm Type
Experimental
Arm Description
Patients receiving mimetic stent. Supera®
Intervention Type
Device
Intervention Name(s)
Pharmacoactive balloon angioplasty. Lutonix®
Intervention Description
Percutaneous transluminal angioplasty with paclitaxel-coated balloon in the arteriosclerosis site to increase blood-flow to the distal arterial areas.
Intervention Type
Device
Intervention Name(s)
Mimetic stent.Supera®
Intervention Description
Multiple intertwined nitinol wires that provide greater radial resistance and allow for even stress distribution. Implanted through percutaneous transluminal angioplasty in the arteriosclerosis site to increase blood-flow to the distal arterial areas.
Primary Outcome Measure Information:
Title
Permeability
Description
Degree of arterial permeability after intervention measured by arterial cartography with ultrasound at 3, 6 and 12 months.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Limb salvage rate
Description
Number (percentage) of limbs that did not undergo further amputation.
Time Frame
12 months
Title
Limb reintervention rate
Description
Number (percentage) of limbs that required reintervention.
Time Frame
12 months
Title
Deaths
Description
Number (percentage) of deaths by any cause.
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients diagnosed of critical lower limb ischemia according to the TASC (TransAtlantic Inter-Society Consensus) working group. Patients admitted to the Vascular Surgery Department of the Bellvitge Hospital University to treat critical lower limb ischemia for endovascular treatment. With involvement of the Popliteal artery in-between the Hunter's canal and the start of the tibial artery branch. WOCBP must use highly effective methods of contraception. Patients who sign the written informed consent. Exclusion Criteria: Patients diagnosed of critical lower limb ischemia according to the TASC working group undergoing medical treatment or open surgery. Patients requiring amputation. Patients who underwent previous revascularization of the same limb (same artery). The main involvement is from an arterial territory other than the popliteal artery. Pregnant women. Inability of overcoming the arterial lesion during the endovascular procedure. Affected artery's diameter <4 mm.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Carlos M Rico, MD
Phone
034 932 60 75 00
Email
carlosmartinezrico@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Malka Huici, MD
Phone
034 932 60 75 00
Email
malkahuici@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xavier M Mestre, MD
Organizational Affiliation
Vascular Surgeon Hospital Universitari de Bellvitge
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Universitari de Bellvitge
City
L'Hospitalet De Llobregat
State/Province
Barcelona
ZIP/Postal Code
08907
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carlos M Rico, MD
Phone
034 932 60 75 00
Email
carlosmartinezrico@gmail.com
First Name & Middle Initial & Last Name & Degree
Malka Huici, MD
Phone
034 932 60 75 00
Email
malkahuici@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Drug-Eluting Balloons vs Mimetic Stents for Popliteal Artery Disease

We'll reach out to this number within 24 hrs